AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 102 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,924,786 | +99.2% | 268,967 | +134.6% | 0.02% | +100.0% |
| Q2 2023 | $2,472,548 | -37.8% | 114,629 | -15.4% | 0.01% | -40.0% |
| Q1 2023 | $3,974,543 | -63.6% | 135,465 | -54.1% | 0.02% | -67.2% |
| Q4 2022 | $10,910,116 | +1.4% | 295,267 | -22.7% | 0.06% | +5.2% |
| Q3 2022 | $10,759,000 | – | 382,212 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,756,050 | $35,415,000 | 3.44% |
| Boxer Capital, LLC | 2,200,000 | $28,270,000 | 1.45% |
| Alpha Wave Global, LP | 617,220 | $7,931,000 | 0.72% |
| Ikarian Capital, LLC | 396,654 | $5,097,000 | 0.67% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 768,603 | $9,877,000 | 0.58% |
| Ikarian Capital, LLC | 250,000 | $3,213,000 | 0.42% |
| 683 Capital Management, LLC | 677,714 | $7,685,000 | 0.41% |
| Perceptive Advisors | 1,474,107 | $18,942,000 | 0.38% |
| VIKING GLOBAL INVESTORS LP | 7,170,536 | $92,141,000 | 0.37% |
| Rock Springs Capital Management LP | 998,307 | $12,828,000 | 0.32% |